Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetes therapy - MIGENIX

Drug Profile

Research programme: diabetes therapy - MIGENIX

Alternative Names: MITO 2915; MITO 3384; MITO 4837

Latest Information Update: 25 May 2005

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MIGENIX
  • Class Small molecules
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 25 May 2005 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 28 Sep 2004 Micrologix Biotech is now called MIGENIX
  • 06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top